The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients
Open accessAbstract
BACKGROUND: Gaucher disease (GD) is the most common lysosomal storage disorder (LSD). Based on a deficient β-glucocerebrosidase it leads to an accumulation of glucosylceramide. Standard diagnostic procedures include measurement of enzyme activity, genetic testing as well as analysis of chitotriosidase and CCL18/PARC as biomarkers. Even though chitotriosidase is the most well-established biomarker in GD, it is not specific for GD. Furthermore, it may be false negative in a significant percentage of GD patients due to mutation. Additionally, chitotriosidase reflects the changes in the course of the disease belatedly. This further enhances the need for a reliable biomarker, especially for the monitoring of the disease and the impact of potential treatments. METHODOLOGY: Here, we evaluated the sensitivity and specificity of the previously reported biomarker Glucosylsphingosine with regard to different control groups (healthy control vs. GD carriers vs. other LSDs). FINDINGS: Only GD patients displayed elevated levels of Glucosylsphingosine higher than 12 ng/ml whereas the comparison controls groups revealed concentrations below the pathological cut-off, verifying the specificity of Glucosylsphingosine as a biomarker for GD. In addition, we evaluated the biomarker before and during enzyme replacement therapy (ERT) in 19 patients, demonstrating a decrease in Glucosylsphingosine over time with the most pronounced reduction within the first 6 months of ERT. Furthermore, our data reveals a correlation between the medical consequence of specific mutations and Glucosylsphingosine. INTERPRETATION: In summary, Glucosylsphingosine is a very promising, reliable and specific biomarker for GD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649 · cited 1×
“The method exploits the mathematical equivalence of the AUC to the Mann-Whitney U-statistic [36].”
MethodMarked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117084 · Cited by 896 · cited 1×
“Obviously, these individuals cannot be monitored by the measurement of plasma chitotriosidase activity [12–13].”
BackgroundVedder, A. C., Cox-Brinkman, J., Hollak, C. E. M., Linthorst, G. E., Groener, J. E. M., Helmond, M. T. J., Scheij, S., & Aerts, J. M. F. G. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.04.013 · Cited by 53 · cited 1×
“In male Fabry patients Vedder and colleagues found evidence of elevated chitotriosidase levels which was reduced to normal after onset of treatment reflecting the lipid accumulation in Fabry patients in macrophages prior to therapy [10].”
Background
Cited by
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020441 · Cited by 868
Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1
Dardis, A., Michelakakis, H., Rozenfeld, P., Fumic, K., Wagner, J., Pavan, E., Fuller, M., Revel-Vilk, S., Hughes, D., Cox, T., et al. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02573-6 · Cited by 61
Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease
Schiffer, V., Santiago-Mujika, E., Flunkert, S., Schmidt, S., Farcher, M., Loeffler, T., Schilcher, I., Posch, M., Neddens, J., Sun, Y., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227077 · Cited by 11
Metadata
- Authors
- Rolfs, A., Giese, A.-K., Grittner, U., Mascher, D., Elstein, D., Zimran, A., Böttcher, T., Lukas, J., Hübner, R., Gölnitz, U., Röhle, A., Dudesek, A., Meyer, W., Wittstock, M., & Mascher, H.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-11-20
- Volume
- 8
- Issue
- 11
- Pages
- e79732
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2082577333
- Cited by
- 197
- References
- 3
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients. https://app.cochat.ai/papers/10.1371/journal.pone.0079732
- The paper
- Rolfs, A., Giese, A.-K., Grittner, U., Mascher, D., Elstein, D., Zimran, A., Böttcher, T., Lukas, J., Hübner, R., Gölnitz, U., Röhle, A., Dudesek, A., Meyer, W., Wittstock, M., & Mascher, H. (2013). Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients. PLoS ONE. https://doi.org/10.1371/journal.pone.0079732
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.